Traders bought shares of AbbVie Inc (NYSE:ABBV) on weakness during trading on Tuesday. $118.42 million flowed into the stock on the tick-up and $31.56 million flowed out of the stock on the tick-down, for a money net flow of $86.86 million into the stock. Of all equities tracked, AbbVie had the 6th highest net in-flow for the day. AbbVie traded down ($0.46) for the day and closed at $97.75

ABBV has been the subject of a number of research analyst reports. BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th. Jefferies Group reaffirmed a “buy” rating and issued a $94.00 target price on shares of AbbVie in a research report on Friday, September 8th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $100.00 target price (up from $85.00) on shares of AbbVie in a research report on Friday, September 8th. Cowen reaffirmed a “hold” rating and issued a $95.00 target price (up from $70.00) on shares of AbbVie in a research report on Monday, September 11th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, September 12th. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $100.26.

The stock has a market capitalization of $156,360.00, a P/E ratio of 23.81, a PEG ratio of 1.37 and a beta of 1.53. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The business had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 EPS. equities research analysts anticipate that AbbVie Inc will post 5.55 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend is Thursday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is presently 62.14%.

In other news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Henry O. Gosebruch sold 18,300 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the transaction, the insider now owns 81,287 shares in the company, valued at approximately $7,360,537.85. The disclosure for this sale can be found here. Insiders sold a total of 494,676 shares of company stock worth $47,237,938 in the last 90 days. Company insiders own 0.23% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Acropolis Investment Management LLC purchased a new position in AbbVie in the second quarter worth $106,000. Hudock Capital Group LLC grew its position in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares in the last quarter. Ffcm LLC grew its position in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares in the last quarter. Bristlecone Advisors LLC purchased a new position in AbbVie in the third quarter worth $113,000. Finally, BDO Wealth Advisors LLC purchased a new position in AbbVie in the second quarter worth $115,000. 69.18% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Traders Buy Shares of AbbVie (ABBV) on Weakness” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://theolympiareport.com/2017/12/28/traders-buy-shares-of-abbvie-abbv-on-weakness-3.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with Analyst Ratings Network's FREE daily email newsletter.